An oral presentation will focus on the induction of autophagy by Tumor Treating Fields

In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented

The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ:NVCR) announced today 13 preclinical presentations highlighting data on Tumor Treating Fields’ mechanism of action at the 22nd Annual Meeting of the Society for Neuro-Oncology (SNO), November 16 through November 19, in San Francisco. These 13 preclinical presentations add to the six clinical data presentations to be shared at SNO this year. In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented. The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference and demonstrates what we believe to be a growing interest in Novocure’s cancer treatment among researchers and clinicians throughout the world.

The 13 presentations include an oral presentation by Dr. Moshe Giladi, Novocure’s Director of Preclinical Research, focusing on the induction of autophagy by Tumor Treating Fields. Autophagy is a fundamental process for degrading and recycling cellular components and is used by tumor cells as a survival mechanism. The presentation concludes that inhibition of autophagy using certain commercially available drugs potentiated the efficacy of Tumor Treating Fields in preclinical tumor models. Additional presentations discuss, among other topics, the potential synergistic effect between Tumor Treating Fields and immunotherapy or radiation therapy.

“Treatment with Tumor Treating Fields is broadly applicable and has consistently shown an antimitotic effect in our preclinical and clinical research to date,” Dr. Giladi said. “Novocure is committed to evolving our understanding of Tumor Treating Fields’ mechanism of action and potential clinical utility through the presentation of important preclinical data.”

Oral presentation

(CBIO-16) Induction of autophagy following TTFields application serves as a survival mechanism mediated by AMPK activation. A. Shteingauz. 2:55 – 3 p.m. PST Friday, November 17. (Location: 5A Metabolomics/Cell Biology/Cell Signaling)

Poster presentations

(EXTH-45) The combination of TTFields and ABT-414 demonstrate superior efficacy against glioma cells. R. Schneiderman. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(CBIO-30) Tumor treating fields (TTFields) inhibit cancer cell migration and invasion by inducing reorganizing of the actin cytoskeleton and formation of cell adhesions. R. Schneiderman. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(QLIF-20) Skin care products compatible with Tumor Treating Fields. M. Lacouture. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(EXTH-66) Glioblastoma cells from a patient post-Tumor Treating Fields (TTFields) therapy are sensitive to TTFields in vitro. S. Michelhaugh. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(CSIG-01) Tumor Treatment Fields downregulate specific transcription factors leading to reduced DNA repair capacity, increased replication stress, the inhibition of mitophagy and enhanced cell death. M. Story. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(EXTH-19) Combination of in vitro Tumor Treating Fields and temozolomide decrease proliferation in patient-derived glioblastoma cell lines. S. Michelhaugh. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate ballroom, B2 level)

(RBIO-07) Tumor Treating Fields (TTFields) Delay DNA Damage Repair Following Radiation Treatment of Glioma Cells: Implications for Irradiation through TTFields Transducer Arrays. M. Giladi. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(IMMU-59) Alternating electric fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. T. Voloshin. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(IMMU-48) Evaluating the in-vitro effects of Tumor Treating Fields on T-cell responses. G. Diamant. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(PDTM-26) Tumor treating fields (TTFields) have anti-proliferative effects on pediatric brain tumor cell lines at clinically deliverable field settings. S. Smith. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(DDIS-15) Synergistic Inhibition of Glioma Cell Proliferation by Withaferin A and Tumor Treating Fields. E. Chang. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

(TMIC-38) Modulation of cancer cell metabolism and immune phenotype by TTFields. E. Wong. 5 to 7 p.m. PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)

About Novocure

Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 23, 2017, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171108005521/en/

Source: Novocure